D. Manning

发表

Response to “A new definition of neuropathic pain”

R. Harden, B. Galer, G. Bennett, 2012, PAIN®.

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

J. Farrar, N. Bellamy, B. Galer, 2003, Pain.

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

David Cella, Charles S Cleeland, Alejandro R Jadad, 2008, The journal of pain : official journal of the American Pain Society.

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations

Richard E. White, J. Heyse, J. Chandler, 2008, PAIN.

Single intrathecal administration of the transcription factor decoy AYX1 prevents acute and chronic pain after incisional, inflammatory, or neuropathic injury

R. Donahue, B. Taylor, T. Brennan, 2014, PAIN®.

Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions.

S. Snyder, J. Stewart, D. Manning, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Intrathecal administration of AYX2 DNA decoy produces a long-term pain treatment in rat models of chronic pain by inhibiting the KLF6, KLF9, and KLF15 transcription factors

R. Donahue, B. Taylor, D. Manning, 2017, Molecular pain.

Editor’s Highlight: Formulation and Toxicology Evaluation of the Intrathecal AYX1 DNA-Decoy in Sprague Dawley Rats

T. Yaksh, D. Manning, D. Yeomans, 2017, Toxicological sciences : an official journal of the Society of Toxicology.

Bradykinin receptors localized by quantitative autoradiography in kidney, ureter, and bladder.

S. Snyder, D. Manning, 1989, The American journal of physiology.

Two bradykinin binding sites with picomolar affinities.

S. Snyder, J. Stewart, D. Manning, 1986, The Journal of pharmacology and experimental therapeutics.

Bradykinin receptor-mediated chloride secretion in intestinal function

S. Snyder, Richard J. Miller, D. Manning, 1982, Nature.

Bradykinin analogues: differential agonist and antagonist activities suggesting multiple receptors

S. Snyder, D. Manning, D. Perry, 1988, British journal of pharmacology.

Characterization of kinin receptors on human synovial cells and upregulation of receptor number by interleukin-1.

D. Proud, J. Bathon, D. Manning, 1992, The Journal of pharmacology and experimental therapeutics.

Pharmacology, pharmacokinetics, and metabolism of the DNA-decoy AYX1 for the prevention of acute and chronic post-surgical pain

R. Donahue, T. Yaksh, D. Manning, 2017, Molecular pain.

[3H]Bradykinin receptor binding in mammalian tissue membranes.

S. Snyder, J. Stewart, R. Innis, 1981, Proceedings of the National Academy of Sciences of the United States of America.

The effects of bradykinin and sequence-related analogs on the response properties of cutaneous nociceptors in monkeys.

R. Meyer, S. Raja, J. Campbell, 1992, Somatosensory & motor research.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, N. Bellamy, 2010, PAIN®.

Bradykinin and Pain

S. Snyder, D. Manning, L. Steranka, 1989 .

New and emerging pharmacological targets for neuropathic pain

D. Manning, 2004, Current pain and headache reports.

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

J. Farrar, N. Bellamy, B. Galer, 2003, Pain.

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, R. Gershon, 2006, Pain.

Reflex sympathetic dystrophy, sympathetically maintained pain, and complex regional pain syndrome: diagnoses of inclusion, exclusion, or confusion?

D. Manning, 2000, Journal of hand therapy : official journal of the American Society of Hand Therapists.

Pain and hyperalgesia after intradermal injection of bradykinin in humans

R. Meyer, S. Raja, D. Manning, 1991, Clinical pharmacology and therapeutics.

ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials.

J. Sloan, B. Reeve, C. Cleeland, 2010, Journal of pain and symptom management.

Lenalidomide for complex regional pain syndrome type 1: lack of efficacy in a phase II randomized study.

R. Harden, J. Arezzo, S. Raja, 2014, The journal of pain : official journal of the American Pain Society.

A randomized, double‐blind, placebo‐controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

A. Forbes, J. Mansfield, J. Zeldis, 2007, Alimentary pharmacology & therapeutics.

Statement nterpreting the Clinical Importance of Treatment Outcomes n Chronic Pain Clinical Trials : IMMPACT Recommendations

K. Schmader, J. Chandler, J. Farrar, 2008 .

Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.

E. Lower, J. Zeldis, S. Fleishman, 2009, Journal of pain and symptom management.

A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and "chemobrain" in adult cancer patients

E. Lower, J. Zeldis, S. Fleishman, 2005 .

A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase

J. Zeldis, D. Manning, R. Rauck, 2016, Pain medicine (Malden, Mass.).

Autoradiographic localization of somatostatin receptors in rat brain.

G. Uhl, W. Vale, D. Manning, 1984, European journal of pharmacology.

Lumbar Epidural Steroid Injections: Is a Clinical Trial Necessary or Appropriate?

D. Manning, M. Hopwood, 1998, Regional Anesthesia & Pain Medicine.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, N. Bellamy, 2010, PAIN®.

Questions of balance in chronic pain

D. Manning, 2007, Pain.

Response to “A new definition of neuropathic pain”

B. Galer, G. Bennett, S. Bruehl, 2012, PAIN®.